Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells

Multidrug resistance (MDR) is one of the leading causes of treatment failure in cancer chemotherapy. One major mechanism of MDR is the overexpressing of ABC transporters, whose inhibitors hold promising potential in antagonizing MDR. Glesatinib is a dual inhibitor of c-Met and SMO that is under phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qingbin, Cai, Chao-Yun, Gao, Hai-Ling, Ren, Liang, Ji, Ning, Gupta, Pranav, Yang, Yuqi, Shukla, Suneet, Ambudkar, Suresh V., Yang, Dong-Hua, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494935/
https://www.ncbi.nlm.nih.gov/pubmed/31106148
http://dx.doi.org/10.3389/fonc.2019.00313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494935/
https://www.ncbi.nlm.nih.gov/pubmed/31106148
http://dx.doi.org/10.3389/fonc.2019.00313

Ejemplares similares